Grifols SA | CIK:0001438569 | 3

  • Filed: 4/6/2018
  • Entity registrant name: Grifols SA (CIK: 0001438569)
  • Generator: Merrill
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1438569/000110465918022787/0001104659-18-022787-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1438569/000110465918022787/grfs-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001438569
  • Open this page in separate window: Click
  • ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory

     

     

     

     

     

    Thousands of Euros

     

     

     

     

     

    Balance at

     

    Translation

     

    Balance at

     

     

     

    Segment

     

    31/12/2015

     

    differences

     

    31/12/2016

     

    Net value

     

     

     

     

     

     

     

     

     

    Grifols UK.Ltd. (UK)

     

    Bioscience

     

    9,362

     

    (1,337

    )

    8,025

     

    Grifols Italia.S.p.A. (Italy)

     

    Bioscience

     

    6,118

     

     

    6,118

     

    Biomat USA, Inc.(USA)

     

    Bioscience

     

    186,907

     

    6,132

     

    193,039

     

    Grifols Australia Pty Ltd. (Australia) / Medion Diagnostics AG (Switzerland)

     

    Diagnostic

     

    9,961

     

    173

     

    10,134

     

    Grifols Therapeutics, Inc. (USA)

     

    Bioscience

     

    2,041,137

     

    67,002

     

    2,108,139

     

    Araclon Biotech, S.L. (Spain)

     

    Diagnostic

     

    6,000

     

     

    6,000

     

    Progenika Biopharma, S.A. (Spain)

     

    Diagnostic

     

    40,516

     

     

    40,516

     

    Grifols Diagnostic (Novartis) (USA, Switzerland and Hong Kong)

     

    Diagnostic

     

    1,232,358

     

    39,666

     

    1,272,024

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    3,532,359

     

    111,636

     

    3,643,995

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Thousands of Euros

     

     

     

     

     

    Balance at

     

    Business

     

    Translation

     

    Balance at

     

     

     

    Segment

     

    31/12/2016

     

    Combination

     

    differences

     

    31/12/2017

     

    Net value

     

     

     

     

     

     

     

     

     

     

     

    Grifols UK.Ltd. (UK)

     

    Bioscience

     

    8,025

     

     

    (280

    )

    7,745

     

    Grifols Italia.S.p.A. (Italy)

     

    Bioscience

     

    6,118

     

     

     

    6,118

     

    Biomat USA, Inc.(USA)

     

    Bioscience

     

    193,039

     

    40,101

     

    (27,886

    )

    205,254

     

    Grifols Australia Pty Ltd. (Australia) / Medion Diagnostics AG (Switzerland)

     

    Diagnostic

     

    10,134

     

     

    (591

    )

    9,543

     

    Grifols Therapeutics, Inc. (USA)

     

    Bioscience

     

    2,108,139

     

     

    (255,234

    )

    1,852,905

     

    Araclon Biotech, S.L. (Spain)

     

    Diagnostic

     

    6,000

     

     

     

    6,000

     

    Progenika Biopharma, S.A. (Spain)

     

    Diagnostic

     

    40,516

     

     

     

    40,516

     

    Grifols Diagnostic (Novartis & Hologic) (USA, Spain and Hong Kong)

     

    Diagnostic

     

    1,272,024

     

    1,466,420

     

    (302,537

    )

    2,435,907

     

    Kiro Grifols S.L. (Spain)

     

    Hospital

     

     

    26,510

     

     

    26,510

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    3,643,995

     

    1,533,031

     

    (586,528

    )

    4,590,498

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    (See note 3)